Drugs in MeSH Category Antineoplastic Agents, Alkylating
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Meitheal | THIOTEPA | thiotepa | POWDER;INTRACAVITARY, INTRAVENOUS, INTRAVESICAL | 216037-002 | Dec 26, 2023 | AP | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Baxter Hlthcare Corp | BENDAMUSTINE HYDROCHLORIDE | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 216078-001 | Dec 15, 2022 | AP | RX | Yes | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Apotex | ALKERAN | melphalan | TABLET;ORAL | 014691-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Cephalon | TREANDA | bendamustine hydrochloride | SOLUTION;INTRAVENOUS | 022249-004 | Sep 13, 2013 | DISCN | Yes | No | 8,791,270*PED | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| Cephalon | TREANDA | bendamustine hydrochloride | POWDER;INTRAVENOUS | 022249-001 | Mar 20, 2008 | AP | RX | Yes | Yes | 8,883,836*PED | ⤷ Start Trial | Y | ⤷ Start Trial | ||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
